Efficacy and Safety of Ionized Atelocollagen Adhesion Barrier (Collabarrier®) in Spine Surgery

NCT ID: NCT07153822

Last Updated: 2025-09-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-15

Study Completion Date

2024-01-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multicenter, randomized, subject- and evaluator-blinded, active-controlled, non-inferiority clinical trial was conducted to evaluate the efficacy and safety of Collabarrier®, a collagen-based adhesion barrier, compared to Guardix-sol in patients undergoing lumbar spine surgery for herniated disc or spinal stenosis.

A total of 69 adult patients scheduled for first-time partial laminectomy or discectomy were enrolled and randomly assigned to receive either Collabarrier® or Guardix-sol. The investigational device (Collabarrier®) is a gel-type atelocollagen formulation designed to prevent postoperative adhesions by acting as a physical barrier between the dura mater and surrounding tissues.

The primary outcome was the mean MRI Scar Score at 6 weeks postoperatively, assessed by independent evaluators blinded to treatment allocation. Secondary outcomes included patient-reported pain scores using a 100-mm Visual Analog Scale (VAS) for low back and leg pain, and functional limitation assessed using the Oswestry Disability Index (ODI), measured at baseline, 3 weeks, and 6 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lumbar Spinal Stenosis Lumbar Disc Herniation Epidural Fibrosis Postoperative Adhesion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Collabarrier®

Group Type EXPERIMENTAL

Collagen-based adhesion barrier

Intervention Type DEVICE

Porcine Atelocollagen (Type I)

Guardix-sol

Group Type ACTIVE_COMPARATOR

Sodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier

Intervention Type DEVICE

Sodium Hyaluronate(HA) + Sodium Carboxymethylcellulose(CMC)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collagen-based adhesion barrier

Porcine Atelocollagen (Type I)

Intervention Type DEVICE

Sodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier

Sodium Hyaluronate(HA) + Sodium Carboxymethylcellulose(CMC)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

adhesion barrier adhesion barrier

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female participants aged 19 years or older
* Patients diagnosed with lumbar disc herniation or lumbar spinal stenosis based on radiological evidence (MRI or CT) showing nerve root compression at one of the following single levels: L3-L4, L4-L5, or L5-S1
* Patients scheduled to undergo their first partial laminectomy or discectomy for the above condition
* Patients who meet at least one of the following criteria (A, B, C):
* A. Have undergone a minimum of 4 weeks of prior conservative treatment within the 6 months prior to Visit 1 (e.g., physical therapy, use of anti-inflammatory drugs, or muscle relaxants)
* B. Experience intolerable pain and are judged by the investigator to require surgery for lumbar disc herniation or spinal stenosis
* C. Have significant progression of neurological functional loss
* Patients who voluntarily provide written informed consent and are able to comply with the study procedures and visit schedule

Exclusion Criteria

* Patients who shows alergic reaction or has previous stroke to main and other ingredients or components of the medical device for this clinical test
* Patients with a medical history of brittle bone
* Patients with a medical history of fracture in lumbar region or ligament injuries by external injury
* Patients who needs to undergo a spine surgery (osteotomy allowable) in addition to partial laminectomy or percutaneous lumbar discectomy for cure of symptom
* Patients with neurological function disorder on intestine/bladder
* Patients with any of such symptoms as excessive exudation, bleeding, acute edema and infection on the part applied
* Patients with Degenerative spinal disorder (other than disc herniation or spinal stenosis) or scoliosis (Cobb's angle is 15° or bigger)
* Patients with any of lymphatic disease, coagulation disoder and/or coagulant taken
* Patients with uncontrolled diabetes that may affect the surgery or the progress after surgery based on the tester's judgment
* Patients with desmosis or autoimmune disease or who has ever taken malignant tumor treatment within 5 years before this surgery
* Patients who has ever undergone a spine surgery on the part for this surgery
* Patients who has ever taken extradural steroid treatment within 2 weeks before surgery or oral steroid drug within 10 days before surgery
* Patients who has ever taken myelogram or lumbar puncture within 24 hours before screening
* Patients with impaired immunity or clinically significant abnormalities in clinical laboratory tests at screening Patients with immunity deteriorated or who shows clinically significant abnormality in lab test items at the moment of screening
* Patients who present clinically severe impairment in cardiovascular, digestive, respiratory, endocrine, or central nervous system, or have a mental illness that significantly affects the trial
* Participated in other clinical trials within 30 days from the screening
* A pregnant woman or lactating woman
* Patients who cannot comply with any requirement of the document form consent for this clinical test from the signing date of signature on the consent till the final day of visit
* Patients determined by the researcher to be non-conformable to this clinical trials.
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DALIM TISSEN Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ajou University Hospital

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Korea University Anam Hospital

Seoul, , South Korea

Site Status

The Catholic University of Korea Eunpyeong St. Mary's Hospital

Seoul, , South Korea

Site Status

The Catholic University of Korea Seoul St. Mary's Hospital

Seoul, , South Korea

Site Status

The Catholic University of Korea St. Vincent's Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DRT-04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Post Marketing Surveillance Study
NCT03366779 ACTIVE_NOT_RECRUITING PHASE4
M6-C Post Approval Study (PAS)
NCT04122248 ACTIVE_NOT_RECRUITING